Molecular Pharmaceutics
[ASAP] Stabilizing Mechanisms of β‑Lactoglobulin in Amorphous Solid Dispersions of Indomethacin
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00397
Molecular Pharmaceutics
[ASAP] Leveraging Biological Buffers for Efficient Messenger RNA Delivery via Lipid Nanoparticles
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00587
Molecular Pharmaceutics
[ASAP] Application of a Simple Short-Range Attraction and Long-Range Repulsion Colloidal Model toward Predicting the Viscosity of Protein Solutions
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00582
Molecular Pharmaceutics
[ASAP] mRNA Treatment Rescues Niemann–Pick Disease Type C1 in Patient Fibroblasts
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00463
Molecular Pharmaceutics
[ASAP] Stable Recombinant Invasion Plasmid Antigen C (IpaC)-Based Single Dose Nanovaccine for Shigellosis
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00378
Molecular Pharmaceutics
[ASAP] Mechanistic Insights into the Activation of Lecithin–Cholesterol Acyltransferase in Therapeutic Nanodiscs Composed of Apolipoprotein A‑I Mimetic Peptides and Phospholipids
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00540
Molecular Pharmaceutics
[ASAP] C‑Terminal Lysine Processing of IgG in Human Suction Blister Fluid: Implications for Subcutaneous Administration
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00506
Molecular Pharmaceutics
[ASAP] Correction to “Enhanced Sensitivity of Cancer Stem Cells to Chemotherapy Using Functionalized Mesoporous Silica Nanoparticles”
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00732
Molecular Pharmaceutics
[ASAP] Tuning Mesoporous Silica Nanoparticles in Novel Avenues of Cancer Therapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00374
Molecular Pharmaceutics
[ASAP] Oral Nanocurcumin Alone or in Combination with Insulin Alleviates STZ-Induced Diabetic Neuropathy in Rats
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00465